manuel teixeira, md, phd head of department of genetics carlos lopes, md, phd

20
CONTRIBUTION OF CHROMOSOME BANDING AND MOLECULAR CYTOGENETIC ANALYSES FOR THE DIAGNOSIS OF SOFT TISSUE AND BONE TUMORS OVER A 6-YEAR- PERIOD Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD Department of Pathology Portuguese Oncology Institute, Porto, Portugal

Upload: terris

Post on 15-Jan-2016

35 views

Category:

Documents


0 download

DESCRIPTION

CONTRIBUTION OF CHROMOSOME BANDING AND MOLECULAR CYTOGENETIC ANALYSES FOR THE DIAGNOSIS OF SOFT TISSUE AND BONE TUMORS OVER A 6-YEAR-PERIOD. Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD Department of Pathology Portuguese Oncology Institute, Porto, Portugal. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

CONTRIBUTION OF CHROMOSOME BANDING AND MOLECULAR

CYTOGENETIC ANALYSES FOR THE DIAGNOSIS OF SOFT TISSUE AND BONE

TUMORS OVER A 6-YEAR-PERIOD

Manuel Teixeira, MD, PhD Head of Department of Genetics

Carlos Lopes, MD, PhDDepartment of Pathology

Portuguese Oncology Institute, Porto, Portugal

Page 2: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD
Page 3: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD
Page 4: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Differential diagnosis:Small round cell tumors

Tumor type Cytogenetics Genes

Ewing’s sarcoma/PNET t(11;22)(q24;q12)t(21;22)(q22;q12)

FLI1/EWSERG/EWS

Alveolar rhabdomyosarcoma t(2;13)(q35;q14)t(1;13)(p36;q14)

PAX3/FKHRPAX7/FKHR

Desmopl. small round cell t. t(11;22)(p13;q12) WT1/EWS

Neuroblastoma del(1p), hsr, dmin MYCN

Non-Hodgkin lymphoma Typical changes IG/V, TCR/V

Page 5: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Ewing’s sarcoma/PNET

3’EWS5’EWS

Page 6: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Alveolar rhabdomyosarcoma with PAX7-FKHR Bone marow; no primary tumor found

3’FKHR5’FKHR

Page 7: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Differential diagnosis: Lipomatous tumors

Tumor type Cytogenetics

Lipoma 12q13~15 changes6p changes13q deletions

Atypical lipoma/WD liposarcoma +r/mar

Lipoblastoma 8q11~13 changes

Fusocellular lipoma 16q13~qter deletions

 Hybernoma 11q13~21 changes

 Liposarcoma- myxoid/round cell t(12;16)(q13;p11)

- pleomorphic Complex changes

Page 8: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Atypical lipoma/Well-differentiated liposarcoma

5’CHOP3’CHOP

Ampl. MDM2/CDK4

Page 9: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Myxoid/round cell liposarcoma

5’CHOP3’CHOP

Page 10: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Differential diagnosis: Fusocellular sarcomas

Tumor type Cytogenetics

Synovial sarcoma t(X;18)(p11;q11)

Fibrosarcoma Complex karyotype

Malign. perypheral nerve sheath t. Complex karyotype

Page 11: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Synovial sarcoma

5’SYT3’SYT

Page 12: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

6942%

4025%

5433%

Pathognomonic

Informative

Non-specific

Types of genetic findings and their relevance for differential diagnosis

N=163/614

Apr. 2001 - Mar. 2007

Page 13: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Patients with a pathognomonic genetic finding

1726%

1420%

1116%

46%

23%

23%

11%

11%

11%

11%

1522%

Well-differentiatedliposarcomaEwing's sarcoma/PNET

Synovial sarcoma

Myxoid/round cellliposarcomaAlveolarrhabdomyosarcomaLipoma

Benign schwanoma

Extraskeletal myxoidchondrosarcomaDermatofibrosarcomaprotuberansLung hamartoma

Clear cell sarcoma

Page 14: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

2

1

5

2

1

11

1

1

1

2

1

2

2

10

12

12

14

58

0% 20% 40% 60% 80% 100%

Extraskeletal myxoid chondrosarcoma

Dermatofibrosarcoma protuberans

Lung hamartoma

Lipoma

Clear cell sarcoma

Benign schwanoma

Alveolar rhabdomyosarcoma

Myxoid/round cell liposarcoma

Well-differentiated liposarcoma

Synovial sarcoma

Ewing's sarcoma/PNET

Total

Desagreement rate in patients with a pathognomonic genetic finding

2 ERMS

Extraskel. myxoid chondrosarcoma

2 lipomas, 2 myxoidlipos; 1 MSFT

Small cell osteos.

1 myxoid lipos;1 sarcoma NOS

Page 15: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Patients with informative but not pathognomonic genetic findings

1128%

1333%

1639% Decisive

Compatible

Not compatible

Page 16: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Patients with informative genetic findingsdecisive for differential diagnosis

328%

218%

19%

19%

19%

19%

19%

19%

Lipoma

Melanoma metastasis

Fibrosarcoma

Carcinoma metastasis

Malignant schwanoma

Tendon sheathsarcomaSarcoma NOS

Malignant solitaryfibrous tumor

Page 17: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Patients with informative genetic findingscompatible with morphologic diagnosis

322%

214%

18%

18%

18%

18%

18%

18%

18%

18%

EmbryonalrhabdomyosarcomaCarcinoma

Renal cell carcinoma

Chondroma

GIST

Malignant fibroushystiocytomaLipoma

Ossifying myositis

PleomorphicrhabdomyosarcomaSmall cell sarcoma

Page 18: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Patients with informative genetic findingsnot compatible with morphologic diagnosis

424%

319%

319%

213%

213%

16%

16%

Malignant schwanoma

Extraskeletal myxoidchondrosarcoma

Ewing's sarcoma/PNET

Myxoid/round cellliposarcoma

Synovial sarcoma

Pleuropulmonar blastoma

Well-differentiatedliposarcoma

Page 19: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Conclusions

42% of the tumors with genetic changes presented a pathognomonic chromosome alteration

Additional 25% of the tumors with genetic changes had an informative result for differential diagnosis

In 16% of the tumors presenting a pathognomonic chromosome change, the initial morphologic diagnosis was changed as a result of the cytogenetic finding

The tumor types that benefited most from the cytogenetic data for their correct diagnosis were alveolar rhabdomyosarcoma, well differentiated liposarcoma, synovial sarcoma, Ewing’s sarcoma, and myxoid liposarcoma

Page 20: Manuel Teixeira, MD, PhD Head of Department of Genetics Carlos Lopes, MD, PhD

Thanks!